GRDN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

2 Analyst Rating

Wall Street analysts forecast GRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRDN is 34.50 USD with a low forecast of 34.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

34.00

Averages

34.50

High

35.00

Current: 0.000

Low

34.00

Averages

34.50

High

35.00

Truist

Buy

maintain

$30 -> $34

2025-11-14

Reason

Truist

Price Target

$30 -> $34

2025-11-14

maintain

Buy

Reason

Truist raised the firm's price target on Guardian Pharmacy to $34 from $30 and keeps a Buy rating on the shares. The firm has updated its model to reflect the company's Q3 earnings beat and guidance raise, the analyst tells investors in a research note. Truist is positive on Guardian's leading positioning in the fragmented long-term care pharmacy industry which carries "brisk overarching secular demand drivers".

Oppenheimer

Outperform

maintain

$30 -> $35

2025-11-11

Reason

Oppenheimer

Price Target

$30 -> $35

2025-11-11

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on Guardian Pharmacy to $35 from $30 and keeps an Outperform rating on the shares following quarterly results. Overall, the results were solid, as Guardian continues a methodical approach to growth that unlocks attractive value over time, the firm says.

Truist

David MacDonald

Buy

maintain

$28 -> $30

2025-09-26

Reason

Truist

David MacDonald

Price Target

$28 -> $30

2025-09-26

maintain

Buy

Reason

Truist analyst David MacDonald raised the firm's price target on Guardian Pharmacy to $30 from $28 and keeps a Buy rating on the shares. The firm remain bullish on Guardian post management meetings highlighting the company's strong positioning in a market with brisk core demand, overarching tailwinds and ongoing expansion opportunity, the analyst tells investors in a research note. Truist adds that Guardian's core trends remain strong, and the firm sees an attractive earnings power opportunity from recently acquired facilities.

Truist

Buy

maintain

$25 -> $28

2025-05-19

Reason

Truist

Price Target

$25 -> $28

2025-05-19

maintain

Buy

Reason

Raymond James

John Ransom

Outperform

maintain

$25 -> $28

2025-05-14

Reason

Raymond James

John Ransom

Price Target

$25 -> $28

2025-05-14

maintain

Outperform

Reason

Raymond James analyst John Ransom raised the firm's price target on Guardian Pharmacy to $28 from $25 and keeps an Outperform rating on the shares. The company's Q1 results were ahead of the firm's model on revenue, but $600,000 below on EBITDA due to some pull-forward on Heartland integration costs and a slight miss on seasonality, the analyst tells investors in a research note. This was a solid quarter with no major surprises outside of the small seasonality change, and Raymond James continues to like Guardian for its solid organic and inorganic growth potential, clean balance sheet with dry powder for M&A, and performance of operational execution.

Truist Securities

David Macdonald

Strong Buy

Maintains

$24 → $25

2025-04-11

Reason

Truist Securities

David Macdonald

Price Target

$24 → $25

2025-04-11

Maintains

Strong Buy

Reason

Truist analyst David MacDonald raised the firm's price target on Guardian Pharmacy to $25 from $24 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm's models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm's expectation of a better environment, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Guardian Pharmacy Services Inc (GRDN.N) is 28.46, compared to its 5-year average forward P/E of 24.95. For a more detailed relative valuation and DCF analysis to assess Guardian Pharmacy Services Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

24.95

Current PE

28.46

Overvalued PE

27.87

Undervalued PE

22.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

15.17

Current EV/EBITDA

17.25

Overvalued EV/EBITDA

16.77

Undervalued EV/EBITDA

13.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.08

Current PS

1.28

Overvalued PS

1.21

Undervalued PS

0.94

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GRDN News & Events

Events Timeline

No data

News

1.0

2025-12-15Newsfilter

Guardian Pharmacy Confirms Participation in 44th Annual J.P. Morgan Healthcare Conference

2.0

2025-12-08NASDAQ.COM

Healthcare Stocks Surge in After-Hours Trading: KYMR, OCUL, POAI Lead the Gains

2.0

2025-10-29NASDAQ.COM

GRDN Surpasses Average Analyst Expectations

People Also Watch

Frequently Asked Questions

What is Guardian Pharmacy Services Inc (GRDN) stock price today?

The current price of GRDN is 30.32 USD — it has decreased -2 % in the last trading day.

What is Guardian Pharmacy Services Inc (GRDN)'s business?

Guardian Pharmacy Services, Inc. is a long-term care pharmacy services company. Through its locally based business model, it partners with long-term care facilities (LTCF0073) to deliver medications, and a comprehensive suite of technology-enabled services designed to enhance care and improve adherence to drug regimens, helping to reduce the cost of care and improve clinical outcomes. Through its locally based pharmacies, the Company utilizes a complex, technology-enabled platform to manage the dispensing and administration of prescriptions to residents of LTCFs over the full prescription lifecycle in order to manage medication risk. Its Guardian Compass platform offers insights to enhance efficiency for its pharmacies, including proprietary real-time operational dashboards and metrics. Its suite of GuardianShield products offers customer and clinical services that benefit both the residents it serves and their caregivers.

What is the price predicton of GRDN Stock?

What is Guardian Pharmacy Services Inc (GRDN)'s revenue for the last quarter?

Guardian Pharmacy Services Inc revenue for the last quarter amounts to 377.43M USD, increased 20.05 % YoY.

What is Guardian Pharmacy Services Inc (GRDN)'s earnings per share (EPS) for the last quarter?

Guardian Pharmacy Services Inc. EPS for the last quarter amounts to 0.16 USD, decreased -108.00 % YoY.

What changes have occurred in the market's expectations for Guardian Pharmacy Services Inc (GRDN)'s fundamentals?

The market is revising Upward the revenue expectations for Guardian Pharmacy Services, Inc. (GRDN) for FY2025, with the revenue forecasts being adjusted by 2.85% over the past three months. During the same period, the stock price has changed by 28.04%.

How many employees does Guardian Pharmacy Services Inc (GRDN). have?

Guardian Pharmacy Services Inc (GRDN) has 3400 emplpoyees as of January 10 2026.

What is Guardian Pharmacy Services Inc (GRDN) market cap?

Today GRDN has the market capitalization of 1.92B USD.